NCT04887311View on ClinicalTrials.gov

MBM-01 (Tempol) for the Treatment of Ataxia Telangiectasia

PHASE2UnknownINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 31, 2021

Primary Completion Date

June 30, 2022

Study Completion Date

December 31, 2022

Conditions
Ataxia Telangiectasia Louis-BarAtaxia Telangiectasia in ChildrenAtaxia Telangiectasia
Interventions
DRUG

MBM-01

Patients will be administered study drug daily for 9 months QD via premarked medicine cups.

Trial Locations (1)

77030

University of Texas Health Science Center at Houston, Houston

Sponsors
All Listed Sponsors
collaborator

The University of Texas Health Science Center, Houston

OTHER

lead

Matrix Biomed, Inc.

INDUSTRY

NCT04887311 - MBM-01 (Tempol) for the Treatment of Ataxia Telangiectasia | Biotech Hunter | Biotech Hunter